1. Clinical & Scientific Overview
Metoclopramide Hydrochloride (TIP-MED-000084, Reference Code [5.16]) is classified under
Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Central & Peripheral Dopamine D2 Antagonist & 5-HT4 Agonist Antiemetic (Schedule H | NLEM 2022).
Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.16], p. 67): Perinorm (Ipca), Reglan, Emnorm — Strengths & Dosage Forms: Tablets: 10 mg; Syrup: 5 mg/5 mL; Injection: 5 mg/mL (2 mL ampoule = 10 mg)
Tablets: 10 mg; Syrup: 5 mg/5 mL; Injection: 5 mg/mL (2 mL ampoule = 10 mg)
3. Mechanism of Action & Pharmacodynamics
Central & Peripheral Dopamine D2 Antagonist & 5-HT4 Agonist Antiemetic (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Central & Peripheral Dopamine D2 Antagonist & 5-HT4 Agonist Antiemetic (Schedule H | NLEM 2022) for Acute nausea and vomiting (postoperative, migraine-associated gastric stasis, chemotherapy), diabetic gastroparesis (short-term <=5 days preferred).
4. Therapeutic Indications & Evidence-Supported Uses
- Acute nausea and vomiting (postoperative, migraine-associated gastric stasis, chemotherapy), diabetic gastroparesis (short-term <=5 days preferred)
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Adults (>=60 kg): 10 mg PO/IM/IV up to TDS (5 mg TDS if weight <60 kg). Maximum duration: 5 DAYS (to prevent irreversible tardive dyskinesia!)
Administration & Meal Timing: Take 30 minutes before meals | 30 Minutes Before Meals (up to TDS)
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Renal: Reduce dose by 50% if CrCl 15–60 mL/min, and by 75% if CrCl <15 mL/min! Hepatic: Reduce dose by 50% in severe cirrhosis
Renal: Reduce dose by 50% if CrCl 15–60 mL/min, and by 75% if CrCl <15 mL/min! Hepatic: Reduce dose by 50% in severe cirrhosis
Renal: Reduce dose by 50% if CrCl 15–60 mL/min, and by 75% if CrCl <15 mL/min! Hepatic: Reduce dose by 50% in severe cirrhosis
7. Contraindications, Precautions & High-Risk Warnings
- CONTRAINDICATED in Parkinson's disease (worsens motor symptoms severely!), epilepsy (lowers seizure threshold), GI obstruction/perforation/haemorrhage, phaeochromocytoma, and children <1 year (avoid in <20 yr due to high acute dystonia rate!)
Key Clinical Precautions: Renal: Reduce dose by 50% if CrCl 15–60 mL/min, and by 75% if CrCl <15 mL/min! Hepatic: Reduce dose by 50% in severe cirrhosis
8. Adverse Effects Profile
- Drowsiness, restlessness, fatigue, hyperprolactinaemia (galactorrhoea)
- Acute extrapyramidal reactions (oculogyric crisis, torticollis, trismus — treat STAT with Promethazine or Trihexyphenidyl!), irreversible Tardive Dyskinesia (with chronic use), Neuroleptic Malignant Syndrome (NMS)
- Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Antagonises Levodopa/Carbidopa and Pramipexole in Parkinson's disease; additive EPS with antipsychotics (Risperidone, Haloperidol, Levosulpiride); additive CNS depression with alcohol/opioids
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.
Pharmacist Patient Counselling Points:
- Patient Counselling Checklist: Never use for more than 5 days; stop immediately and seek medical care if you develop neck stiffness, jaw spasms, eye rolling, or hand tremors; contraindicated in Parkinson's disease
- Meal & Clock Timing Instruction: Take 30 minutes before meals (30 Minutes Before Meals (up to TDS))
- Missed Dose Protocol: Use PRN or skip missed dose; never exceed 30 mg/day or 5 days
- Geriatric Dispensing Pearl: Avoid in older adults (AGS Beers 2023) except for short-term gastroparesis — high risk of drug-induced Parkinsonism and tardive dyskinesia
Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Tablets: 10 mg; Syrup: 5 mg/5 mL; Injection: 5 mg/mL (2 mL ampoule = 10 mg)
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.16] (p. 67)
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [5.20] Ursodeoxycholic Acid (UDCA) — Hydrophilic Cytoprotective & Choleretic Bile Acid (Schedule H)
- [5.21] Rifaximin & L-Ornithine L-Aspartate (LOLA) — Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying
- [5.22] Mesalazine (5-Aminosalicylic Acid — 5-ASA) & Sulfasalazine — Colonic Topical Anti-Inflammatory Salicylate & Disease-Modifying
- [5.8]-CMP21 Betahistine Dihydrochloride, Cinnarizine & Flunarizine — Synthetic Non-Absorbable Disaccharide (Galactose-Fructose); Osmot
